Targeting TNF-α with infliximab decreases the expression of IL-6 and CCL1 in tolerant iDCs at 27h.

<p>Soluble chimeric monoclonal anti-TNF-α antibody (infliximab) was added to the culture supernatant in a therapeutic concentration (white bars) and the effects on gene and protein expression were monitored by QRT-PCR (A–E) and ELISA (F). Samples without infliximab treatment (gray bars) were used as controls. While infliximab pre-treatment has no effect on the expression of TNF-α (A), TNFAIP3 (B), TNFAIP8 (C), IL-6 (D) and CCL1 (E, F) in naïve and induced iDCs, it partially releases the inhibition of TNFAIP8 (C) and significantly dowregulates the expression of IL-6 (D) and CCL-1 (E, F) in tolerant iDCs. The ratio of each mRNA relative to the 18S rRNA was calculated using the 2^-ΔΔCT method. Data are representative of 3 or more independent experiments and are presented as interquartile range (box) with median (horizontal black bar) and minimum and maximum values. The significance of differences between sets of data was determined by Student’s paired t-test using SPSS Statistics; *<i>p</i><0.05.